These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

713 related items for PubMed ID: 32101640

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH, Cheng YF, Lu AD, Wang Y, Zuo YX, Yan CH, Wu J, Sun YQ, Suo P, Chen YH, Chen H, Jia YP, Liu KY, Han W, Xu LP, Zhang LP, Huang XJ.
    BMC Cancer; 2020 Jun 15; 20(1):553. PubMed ID: 32539815
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.
    Yoon JH, Kim HJ, Shin SH, Yahng SA, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Lim JH.
    Eur J Haematol; 2013 Aug 15; 91(2):112-21. PubMed ID: 23672350
    [Abstract] [Full Text] [Related]

  • 6. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ, Wang Y, Zhu HH, Gale RP, Zhang MJ, Jiang Q, Jiang H, Xu LP, Chen H, Zhang XH, Liu YR, Lai YY, Jiang B, Liu KY, Huang XJ.
    Chin J Cancer; 2016 May 19; 35():46. PubMed ID: 27197573
    [Abstract] [Full Text] [Related]

  • 7. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
    Qin YZ, Wang Y, Xu LP, Zhang XH, Chen H, Han W, Chen YH, Wang FR, Wang JZ, Chen Y, Mo XD, Zhao XS, Chang YJ, Liu KY, Huang XJ.
    J Hematol Oncol; 2017 Feb 06; 10(1):44. PubMed ID: 28166825
    [Abstract] [Full Text] [Related]

  • 8. Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression.
    Xiaosu Z, Leqing C, Yazhen Q, Yu W, Xiaohui Z, Lanping X, Xiaojun H, Yingjun C.
    Ann Hematol; 2019 Jan 06; 98(1):73-81. PubMed ID: 30159599
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
    Duan W, Liu X, Jia J, Wang J, Gong L, Jiang Q, Zhao T, Wang Y, Zhang X, Xu L, Zhao X, Qin Y, Shi H, Chang Y, Huang X, Jiang H.
    Br J Haematol; 2021 Jan 06; 192(2):265-271. PubMed ID: 32588434
    [Abstract] [Full Text] [Related]

  • 13. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.
    Hoyos M, Nomdedeu JF, Esteve J, Duarte R, Ribera JM, Llorente A, Escoda L, Bueno J, Tormo M, Gallardo D, de Llano MPQ, Martí JM, Aventín A, Mangues R, Brunet S, Sierra J.
    Eur J Haematol; 2013 Sep 06; 91(3):209-218. PubMed ID: 23646898
    [Abstract] [Full Text] [Related]

  • 14. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z, Guo M, Zhang Y, Xu S, Cheng H, Wu J, Zhang W, Hu X, Yang J, Wang J, Tang G.
    Int J Lab Hematol; 2019 Oct 06; 41(5):607-614. PubMed ID: 31162830
    [Abstract] [Full Text] [Related]

  • 15. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
    Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H.
    Blood Adv; 2020 Jan 14; 4(1):66-75. PubMed ID: 31899799
    [Abstract] [Full Text] [Related]

  • 16. Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11.
    Cho BS, Min GJ, Park SS, Park S, Jeon YW, Shin SH, Yahng SA, Yoon JH, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Kim M, Kim Y, Kim HJ.
    Bone Marrow Transplant; 2021 Nov 14; 56(11):2682-2689. PubMed ID: 34183780
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
    Doubek M, Palasek I, Pospisil Z, Borsky M, Klabusay M, Brychtova Y, Jurcek T, Jeziskova I, Krejci M, Dvorakova D, Mayer J.
    Exp Hematol; 2009 Jun 14; 37(6):659-72. PubMed ID: 19463768
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.
    Ommen HB, Schnittger S, Jovanovic JV, Ommen IB, Hasle H, Østergaard M, Grimwade D, Hokland P.
    Blood; 2010 Jan 14; 115(2):198-205. PubMed ID: 19901261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.